{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["SuperDRUG2 database", "bromodomain-containing protein 4", "cancer disease", "molecular docking", "molecular dynamics simulations"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37570684", "DateCompleted": {"Year": "2023", "Month": "08", "Day": "14"}, "DateRevised": {"Year": "2023", "Month": "08", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "07", "Day": "28"}], "Language": ["eng"], "ELocationID": ["5713", "10.3390/molecules28155713"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "28", "Issue": "15", "PubDate": {"Year": "2023", "Month": "Jul", "Day": "28"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Pyronaridine as a Bromodomain-Containing Protein 4-<i>N</i>-Terminal Bromodomain (BRD4-BD1) Inhibitor: <i>In Silico</i> Database Mining, Molecular Docking, and Molecular Dynamics Simulation.", "Abstract": {"AbstractText": ["BRD4 (bromodomain-containing protein 4) is an epigenetic reader that realizes histone proteins and promotes the transcription of genes linked to cancer progression and non-cancer diseases such as acute heart failure and severe inflammation. The highly conserved <i>N</i>-terminal bromodomain (BD1) recognizes acylated lysine residues to organize the expression of genes. As such, BD1 is essential for disrupting BRD4 interactions and is a promising target for cancer treatment. To identify new BD1 inhibitors, a SuperDRUG2 database that contains more than 4600 pharmaceutical compounds was screened using <i>in silico</i> techniques. The efficiency of the AutoDock Vina1.1.2 software to anticipate inhibitor-BRD4-BD1 binding poses was first evaluated based on the co-crystallized R6S ligand in complex with BRD4-BD1. From database screening, the most promising BRD4-BD1 inhibitors were subsequently submitted to molecular dynamics (MD) simulations integrated with an MM-GBSA approach. MM-GBSA computations indicated promising BD1 binding with a benzonaphthyridine derivative, pyronaridine (SD003509), with an energy prediction (\u0394<i>G</i><sub>binding</sub>) of -42.7 kcal/mol in comparison with -41.5 kcal/mol for a positive control inhibitor (R6S). Pharmacokinetic properties predicted oral bioavailability for both ligands, while post-dynamic analyses of the BRD4-BD1 binding pocket demonstrated greater stability for pyronaridine. These results confirm that <i>in silico</i> studies can provide insight into novel protein-ligand regulators, specifically that pyronaridine is a potential cancer drug candidate."]}, "AuthorList": [{"Identifier": ["0000-0003-4819-2040"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt."}, {"Identifier": [], "Affiliation": "School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4000, South Africa."}], "LastName": "Ibrahim", "ForeName": "Mahmoud A A", "Initials": "MAA"}, {"Identifier": ["0009-0006-8582-9759"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt."}], "LastName": "Abdelhamid", "ForeName": "Mahmoud M H", "Initials": "MMH"}, {"Identifier": ["0000-0001-8667-664X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt."}], "LastName": "Abdeljawaad", "ForeName": "Khlood A A", "Initials": "KAA"}, {"Identifier": ["0000-0003-3527-0126"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt."}], "LastName": "Abdelrahman", "ForeName": "Alaa H M", "Initials": "AHM"}, {"Identifier": ["0000-0003-2474-076X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt."}], "LastName": "Mekhemer", "ForeName": "Gamal A H", "Initials": "GAH"}, {"Identifier": ["0000-0003-2579-6351"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt."}], "LastName": "Sidhom", "ForeName": "Peter A", "Initials": "PA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia."}], "LastName": "Sayed", "ForeName": "Shaban R M", "Initials": "SRM"}, {"Identifier": ["0000-0003-1644-723X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry & Biochemistry, Texas Tech University, Lubbock, TX 79409, USA."}], "LastName": "Par\u00e9", "ForeName": "Paul W", "Initials": "PW"}, {"Identifier": ["0000-0002-0343-4969"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry of Medicinal Plants Department, National Research Centre, 33 El-Bohouth St., Dokki, Giza 12622, Egypt."}], "LastName": "Hegazy", "ForeName": "Mohamed-Elamir F", "Initials": "MF"}, {"Identifier": ["0000-0003-3512-1593"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, The American University in Cairo, New Cairo 11835, Egypt."}], "LastName": "Shoeib", "ForeName": "Tamer", "Initials": "T"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Nuclear Proteins"}, {"RegistryNumber": "TD3P7Q3SG6", "NameOfSubstance": "pyronaridine"}, {"RegistryNumber": "0", "NameOfSubstance": "Bromodomain Containing Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Transcription Factors"}, {"RegistryNumber": "0", "NameOfSubstance": "Ligands"}, {"RegistryNumber": "0", "NameOfSubstance": "Cell Cycle Proteins"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Molecular Dynamics Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": ["metabolism"], "DescriptorName": "Nuclear Proteins"}, {"QualifierName": [], "DescriptorName": "Bromodomain Containing Proteins"}, {"QualifierName": ["metabolism"], "DescriptorName": "Transcription Factors"}, {"QualifierName": [], "DescriptorName": "Ligands"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cell Cycle Proteins"}], "CoiStatement": "The authors declare that they have no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Arrowsmith C.H., Bountra C., Fish P.V., Lee K., Schapira M. Epigenetic protein families: A new frontier for drug discovery. Nat. Rev. Drug Discov. 2012;11:384\u2013400. doi: 10.1038/nrd3674.", "ArticleIdList": ["10.1038/nrd3674", "22498752"]}, {"Citation": "Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T., et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149:214\u2013231. doi: 10.1016/j.cell.2012.02.013.", "ArticleIdList": ["10.1016/j.cell.2012.02.013", "PMC3326523", "22464331"]}, {"Citation": "Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067\u20131073. doi: 10.1038/nature09504.", "ArticleIdList": ["10.1038/nature09504", "PMC3010259", "20871596"]}, {"Citation": "Owen D.J., Ornaghi P., Yang J.C., Lowe N., Evans P.R., Ballario P., Neuhaus D., Filetici P., Travers A.A. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J. 2000;19:6141\u20136149. doi: 10.1093/emboj/19.22.6141.", "ArticleIdList": ["10.1093/emboj/19.22.6141", "PMC305837", "11080160"]}, {"Citation": "Filippakopoulos P., Knapp S. The bromodomain interaction module. FEBS J. 2012;586:2692\u20132704. doi: 10.1016/j.febslet.2012.04.045.", "ArticleIdList": ["10.1016/j.febslet.2012.04.045", "22710155"]}, {"Citation": "Dhalluin C., Carlson J.E., Zeng L., He C., Aggarwal A.K., Zhou M.M. Structure and ligand of a histone acetyltransferase bromodomain. Nature. 1999;399:491\u2013496. doi: 10.1038/20974.", "ArticleIdList": ["10.1038/20974", "10365964"]}, {"Citation": "Zeng L., Zhou M.M. Bromodomain: An acetyl-lysine binding domain. FEBS J. 2002;513:124\u2013128. doi: 10.1016/S0014-5793(01)03309-9.", "ArticleIdList": ["10.1016/S0014-5793(01)03309-9", "11911891"]}, {"Citation": "Chen R., Yik J.H., Lew Q.J., Chao S.H. Brd4 and HEXIM1: Multiple roles in P-TEFb regulation and cancer. Biomed Res. Int. 2014;2014:232870. doi: 10.1155/2014/232870.", "ArticleIdList": ["10.1155/2014/232870", "PMC3925632", "24592384"]}, {"Citation": "Cheng Z., Gong Y., Ma Y., Lu K., Lu X., Pierce L.A., Thompson R.C., Muller S., Knapp S., Wang J. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin. Cancer Res. 2013;19:1748\u20131759. doi: 10.1158/1078-0432.CCR-12-3066.", "ArticleIdList": ["10.1158/1078-0432.CCR-12-3066", "PMC4172367", "23403638"]}, {"Citation": "Gacias M., Gerona-Navarro G., Plotnikov A.N., Zhang G., Zeng L., Kaur J., Moy G., Rusinova E., Rodriguez Y., Matikainen B., et al. Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression. Chem. Biol. 2014;21:841\u2013854. doi: 10.1016/j.chembiol.2014.05.009.", "ArticleIdList": ["10.1016/j.chembiol.2014.05.009", "PMC4104156", "24954007"]}, {"Citation": "Andrieu G., Belkina A.C., Denis G.V. Clinical trials for BET inhibitors run ahead of the science. Drug Discov. Today Technol. 2016;19:45\u201350. doi: 10.1016/j.ddtec.2016.06.004.", "ArticleIdList": ["10.1016/j.ddtec.2016.06.004", "PMC5116321", "27769357"]}, {"Citation": "Liu Z., Wang P., Chen H., Wold E.A., Tian B., Brasier A.R., Zhou J. Drug Discovery Targeting Bromodomain-Containing Protein 4. J. Med. Chem. 2017;60:4533\u20134558. doi: 10.1021/acs.jmedchem.6b01761.", "ArticleIdList": ["10.1021/acs.jmedchem.6b01761", "PMC5464988", "28195723"]}, {"Citation": "Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524\u2013528. doi: 10.1038/nature10334.", "ArticleIdList": ["10.1038/nature10334", "PMC3328300", "21814200"]}, {"Citation": "Hu Y., Zhou J., Ye F., Xiong H., Peng L., Zheng Z., Xu F., Cui M., Wei C., Wang X., et al. BRD4 inhibitor inhibits colorectal cancer growth and metastasis. Int. J. Mol. Sci. 2015;16:1928\u20131948. doi: 10.3390/ijms16011928.", "ArticleIdList": ["10.3390/ijms16011928", "PMC4307342", "25603177"]}, {"Citation": "Lee D.H., Qi J., Bradner J.E., Said J.W., Doan N.B., Forscher C., Yang H., Koeffler H.P. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Int. J. Cancer. 2015;136:2055\u20132064. doi: 10.1002/ijc.29269.", "ArticleIdList": ["10.1002/ijc.29269", "PMC4824295", "25307878"]}, {"Citation": "Bid H.K., Kerk S. BET bromodomain inhibitor (JQ1) and tumor angiogenesis. Oncoscience. 2016;3:316\u2013317. doi: 10.18632/oncoscience.326.", "ArticleIdList": ["10.18632/oncoscience.326", "PMC5235918", "28105454"]}, {"Citation": "Bid H.K., Phelps D.A., Xaio L., Guttridge D.C., Lin J., London C., Baker L.H., Mo X., Houghton P.J. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol. Cancer Ther. 2016;15:1018\u20131028. doi: 10.1158/1535-7163.MCT-15-0567.", "ArticleIdList": ["10.1158/1535-7163.MCT-15-0567", "PMC4873398", "26908627"]}, {"Citation": "Hao J., Yang Z., Wang L., Zhang Y., Shu Y., Jiang L., Hu Y., Lv W., Dong P., Liu Y. Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway. Int. J. Oncol. 2017;51:823\u2013831. doi: 10.3892/ijo.2017.4081.", "ArticleIdList": ["10.3892/ijo.2017.4081", "PMC5564407", "28766687"]}, {"Citation": "Chiang C.M. Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision. Chem. Biol. 2014;21:804\u2013806. doi: 10.1016/j.chembiol.2014.07.003.", "ArticleIdList": ["10.1016/j.chembiol.2014.07.003", "PMC4137397", "25036774"]}, {"Citation": "Picaud S., Wells C., Felletar I., Brotherton D., Martin S., Savitsky P., Diez-Dacal B., Philpott M., Bountra C., Lingard H., et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl. Acad. Sci. USA. 2013;110:19754\u201319759. doi: 10.1073/pnas.1310658110.", "ArticleIdList": ["10.1073/pnas.1310658110", "PMC3856850", "24248379"]}, {"Citation": "Liu Z., Tian B., Chen H., Wang P., Brasier A.R., Zhou J. Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Eur. J. Med. Chem. 2018;151:450\u2013461. doi: 10.1016/j.ejmech.2018.04.006.", "ArticleIdList": ["10.1016/j.ejmech.2018.04.006", "PMC5924617", "29649741"]}, {"Citation": "Lin S., Du L. The therapeutic potential of BRD4 in cardiovascular disease. Hypertens. Res. 2020;43:1006\u20131014. doi: 10.1038/s41440-020-0459-4.", "ArticleIdList": ["10.1038/s41440-020-0459-4", "32409773"]}, {"Citation": "Ding D., Zheng R., Tian Y., Jimenez R., Hou X., Weroha S.J., Wang L., Shi L., Huang H. Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. Nat. Commun. 2022;13:6311. doi: 10.1038/s41467-022-34024-y.", "ArticleIdList": ["10.1038/s41467-022-34024-y", "PMC9588789", "36274096"]}, {"Citation": "Lu T., Lu W., Luo C. A patent review of BRD4 inhibitors (2013\u20132019) Expert Opin. Ther. Pat. 2020;30:57\u201381. doi: 10.1080/13543776.2020.1702645.", "ArticleIdList": ["10.1080/13543776.2020.1702645", "31815566"]}, {"Citation": "Karim M.R., Schonbrunn E. Crystal structure of the first bromodomain (BD1) of human BRD4 in complex with dual BRD4-JAK2 inhibitor MA9-086. 2021.  [(accessed on 9 June 2023)].  Available online:  https://www.wwpdb.org/pdb?id=pdb_00007rek."}, {"Citation": "McInnes C. Virtual screening strategies in drug discovery. Curr. Opin. Chem. Biol. 2007;11:494\u2013502. doi: 10.1016/j.cbpa.2007.08.033.", "ArticleIdList": ["10.1016/j.cbpa.2007.08.033", "17936059"]}, {"Citation": "Hughes J.P., Rees S., Kalindjian S.B., Philpott K.L. Principles of early drug discovery. Br. J. Pharmacol. 2011;162:1239\u20131249. doi: 10.1111/j.1476-5381.2010.01127.x.", "ArticleIdList": ["10.1111/j.1476-5381.2010.01127.x", "PMC3058157", "21091654"]}, {"Citation": "Croft S.L., Duparc S., Arbe-Barnes S.J., Craft J.C., Shin C.S., Fleckenstein L., Borghini-Fuhrer I., Rim H.J. Review of pyronaridine anti-malarial properties and product characteristics. Malar. J. 2012;11:270. doi: 10.1186/1475-2875-11-270.", "ArticleIdList": ["10.1186/1475-2875-11-270", "PMC3483207", "22877082"]}, {"Citation": "Garbuzenko O.B., Kbah N., Kuzmov A., Pogrebnyak N., Pozharov V., Minko T. Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers. J. Control. Release. 2019;296:225\u2013231. doi: 10.1016/j.jconrel.2019.01.025.", "ArticleIdList": ["10.1016/j.jconrel.2019.01.025", "PMC6461390", "30677435"]}, {"Citation": "Cholon D.M., Esther C.R., Jr., Gentzsch M. Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation. Expert Rev. Precis. Med. Drug Dev. 2016;1:235\u2013243. doi: 10.1080/23808993.2016.1175299.", "ArticleIdList": ["10.1080/23808993.2016.1175299", "PMC4963025", "27482545"]}, {"Citation": "Goekjian P.G., Jirousek M.R. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin. Investig. Drugs. 2001;10:2117\u20132140. doi: 10.1517/13543784.10.12.2117.", "ArticleIdList": ["10.1517/13543784.10.12.2117", "11772309"]}, {"Citation": "De Vivo M., Masetti M., Bottegoni G., Cavalli A. Role of molecular dynamics and related methods in drug discovery. J. Med. Chem. 2016;59:4035\u20134061. doi: 10.1021/acs.jmedchem.5b01684.", "ArticleIdList": ["10.1021/acs.jmedchem.5b01684", "26807648"]}, {"Citation": "Kerrigan J.E. Molecular dynamics simulations in drug design. In: Kortagere S., editor. In Silico Models for Drug Discovery. Humana Press; Totowa, NJ, USA: 2013. pp. 95\u2013113.", "ArticleIdList": ["10.1007/978-1-62703-342-8_7", "23568466"]}, {"Citation": "Pires D.E., Blundell T.L., Ascher D.B. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J. Med. Chem. 2015;58:4066\u20134072. doi: 10.1021/acs.jmedchem.5b00104.", "ArticleIdList": ["10.1021/acs.jmedchem.5b00104", "PMC4434528", "25860834"]}, {"Citation": "Dahlgren D., Lennernas H. Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches. Pharmaceutics. 2019;11:411. doi: 10.3390/pharmaceutics11080411.", "ArticleIdList": ["10.3390/pharmaceutics11080411", "PMC6723276", "31412551"]}, {"Citation": "Han Y., Zhang J., Hu C.Q., Zhang X., Ma B., Zhang P. In silico ADME and toxicity prediction of ceftazidime and its impurities. Front. Pharmacol. 2019;10:434\u2013443. doi: 10.3389/fphar.2019.00434.", "ArticleIdList": ["10.3389/fphar.2019.00434", "PMC6491819", "31068821"]}, {"Citation": "Gordon J.C., Myers J.B., Folta T., Shoja V., Heath L.S., Onufriev A. H++: A server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005;33:W368\u2013W371. doi: 10.1093/nar/gki464.", "ArticleIdList": ["10.1093/nar/gki464", "PMC1160225", "15980491"]}, {"Citation": "Siramshetty V.B., Eckert O.A., Gohlke B.O., Goede A., Chen Q., Devarakonda P., Preissner S., Preissner R. SuperDRUG2: A one stop resource for approved/marketed drugs. Nucleic Acids Res. 2018;46:D1137\u2013D1143. doi: 10.1093/nar/gkx1088.", "ArticleIdList": ["10.1093/nar/gkx1088", "PMC5753395", "29140469"]}, {"Citation": "OMEGA. OpenEye Scientific Software; Santa Fe, NM, USA: 2013. version 2.5.1.4."}, {"Citation": "Hawkins P.C., Skillman A.G., Warren G.L., Ellingson B.A., Stahl M.T. Conformer generation with OMEGA: Algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J. Chem. Inf. Model. 2010;50:572\u2013584. doi: 10.1021/ci100031x.", "ArticleIdList": ["10.1021/ci100031x", "PMC2859685", "20235588"]}, {"Citation": "SZYBKI. OpenEye Scientific Software; Santa Fe, NM, USA: 2016. version 1.9.0.3."}, {"Citation": "Halgren T.A. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 1999;20:720\u2013729. doi: 10.1002/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X.", "ArticleIdList": ["10.1002/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X", "34376030"]}, {"Citation": "Trott O., Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455\u2013461. doi: 10.1002/jcc.21334.", "ArticleIdList": ["10.1002/jcc.21334", "PMC3041641", "19499576"]}, {"Citation": "Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785\u20132791. doi: 10.1002/jcc.21256.", "ArticleIdList": ["10.1002/jcc.21256", "PMC2760638", "19399780"]}, {"Citation": "Varadwaj A., Varadwaj P.R., Yamashita K. Do surfaces of positive electrostatic potential on different halogen derivatives in molecules attract? like attracting like! J. Comput. Chem. 2018;39:343\u2013350. doi: 10.1002/jcc.25125.", "ArticleIdList": ["10.1002/jcc.25125", "29226338"]}, {"Citation": "Ibrahim M.A.A., Abdelrahman A.H.M., Jaragh-Alhadad L.A., Atia M.A.M., Alzahrani O.R., Ahmed M.N., Moustafa M.S., Soliman M.E.S., Shawky A.M., Pare P.W., et al. Exploring Toxins for Hunting SARS-CoV-2 Main Protease Inhibitors: Molecular Docking, Molecular Dynamics, Pharmacokinetic Properties, and Reactome Study. Pharmaceuticals. 2022;15:153. doi: 10.3390/ph15020153.", "ArticleIdList": ["10.3390/ph15020153", "PMC8875976", "35215266"]}, {"Citation": "Ibrahim M.A.A., Badr E.A.A., Abdelrahman A.H.M., Almansour N.M., Shawky A.M., Mekhemer G.A.H., Alrumaihi F., Moustafa M.F., Atia M.A.M. Prospective drug candidates as human multidrug transporter ABCG2 inhibitors: An in silico drug discovery study. Cell Biochem. Biophys. 2021;79:189\u2013200. doi: 10.1007/s12013-021-00985-y.", "ArticleIdList": ["10.1007/s12013-021-00985-y", "33954893"]}, {"Citation": "Ibrahim M.A.A., Abdeljawaad K.A.A., Abdelrahman A.H.M., Alzahrani O.R., Alshabrmi F.M., Khalaf E., Moustafa M.F., Alrumaihi F., Allemailem K.S., Soliman M.E.S., et al. Non-beta-lactam allosteric inhibitors target methicillin-resistant staphylococcus aureus: An in silico drug discovery study. Antibiotics. 2021;10:934\u2013956. doi: 10.3390/antibiotics10080934.", "ArticleIdList": ["10.3390/antibiotics10080934", "PMC8388891", "34438984"]}, {"Citation": "Maier J.A., Martinez C., Kasavajhala K., Wickstrom L., Hauser K.E., Simmerling C. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 2015;11:3696\u20133713. doi: 10.1021/acs.jctc.5b00255.", "ArticleIdList": ["10.1021/acs.jctc.5b00255", "PMC4821407", "26574453"]}, {"Citation": "Wang J., Wolf R.M., Caldwell J.W., Kollman P.A., Case D.A. Development and testing of a general amber force field. J. Comput. Chem. 2004;25:1157\u20131174. doi: 10.1002/jcc.20035.", "ArticleIdList": ["10.1002/jcc.20035", "15116359"]}, {"Citation": "Bayly C.I., Cieplak P., Cornell W.D., Kollman P.A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges\u2014The RESP model. J. Phys. Chem. 1993;97:10269\u201310280. doi: 10.1021/j100142a004.", "ArticleIdList": ["10.1021/j100142a004"]}, {"Citation": "Mishra B.K., Karthikeyan S., Ramanathan V. Tuning the C-H...Pi interaction by different substitutions in benzene-acetylene complexes. J. Chem. Theory Comput. 2012;8:1935\u20131942. doi: 10.1021/ct300100h.", "ArticleIdList": ["10.1021/ct300100h", "26593828"]}, {"Citation": "Dassault Syst\u00e8mes BIOVIA, Discovery Studio Visualizer. Dassault Syst\u00e8mes; San Diego, CA, USA: 2019. version 2019."}, {"Citation": "Massova I., Kollman P.A. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect. Drug Discov. 2000;18:113\u2013135. doi: 10.1023/A:1008763014207.", "ArticleIdList": ["10.1023/A:1008763014207"]}, {"Citation": "Hou T., Wang J., Li Y., Wang W. Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. J. Comput. Chem. 2011;32:866\u2013877. doi: 10.1002/jcc.21666.", "ArticleIdList": ["10.1002/jcc.21666", "PMC3043139", "20949517"]}, {"Citation": "Wang E., Sun H., Wang J., Wang Z., Liu H., Zhang J.Z.H., Hou T. End-point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design. Chem. Rev. 2019;119:9478\u20139508. doi: 10.1021/acs.chemrev.9b00055.", "ArticleIdList": ["10.1021/acs.chemrev.9b00055", "31244000"]}, {"Citation": "Shen M., Tian S., Li Y., Li Q., Xu X., Wang J., Hou T. Drug-likeness analysis of traditional Chinese medicines: 1. property distributions of drug-like compounds, non-drug-like compounds and natural compounds from traditional Chinese medicines. J. Cheminformatics. 2012;4:31. doi: 10.1186/1758-2946-4-31.", "ArticleIdList": ["10.1186/1758-2946-4-31", "PMC3538521", "23181938"]}, {"Citation": "Zhao Y.H., Abraham M.H., Le J., Hersey A., Luscombe C.N., Beck G., Sherborne B., Cooper I. Rate-limited steps of human oral absorption and QSAR studies. Pharm. Res. 2002;19:1446\u20131457. doi: 10.1023/A:1020444330011.", "ArticleIdList": ["10.1023/A:1020444330011", "12425461"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "6", "Day": "10"}, {"Year": "2023", "Month": "7", "Day": "21"}, {"Year": "2023", "Month": "7", "Day": "25"}, {"Year": "2023", "Month": "8", "Day": "14", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "8", "Day": "12", "Hour": "10", "Minute": "51"}, {"Year": "2023", "Month": "8", "Day": "12", "Hour": "1", "Minute": "17"}, {"Year": "2023", "Month": "7", "Day": "28"}], "PublicationStatus": "epublish", "ArticleIdList": ["37570684", "PMC10420099", "10.3390/molecules28155713", "molecules28155713"]}}], "PubmedBookArticle": []}